Abstract
Executive Summary
Breast cancer is the leading cause of cancer-related mortality among women
worldwide. High unmet needs still persist for this tumor type. Despite recent
drug approvals in the adjuvant and metastatic setting, the overall survival
remains below five years.
There are today more than 340 therapeutics targeting breast cancer, from early
preclinical to marketed drugs. Breast Cancer Drug Pipeline Update lists all
drugs and gives you a progress analysis on each one of them. Identified drugs
are linked to 165 different targets. These targets are further categorized on
the CD-ROM by 49 classifications of molecular function and with pathway
referals to BioCarta, KEGG and NetPath. Read more below on how the Breast
Cancer Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
View Cart
